nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

23.03.2019 | Focussed Research Review

The role of immune infiltrates as prognostic biomarkers in patients with breast cancer

verfasst von: Constantin N. Baxevanis, Michael Sofopoulos, Sotirios P. Fortis, Sonia A. Perez

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

The presence of immune infiltrates in the tumor microenvironment has been documented in many types of cancer. Moreover, the preexistent or endogenous immunity which consists of interactions between intratumoral lymphocytes and tumor cells is mostly relevant for the successful application of various anticancer therapies, including standard chemotherapy, immune checkpoint inhibition-based immunotherapy and targeted therapies. The immunoscore defines densities of intratumoral immune infiltrates which determine poor or favorable prognosis depending on their quantity and quality in the tumor compartments. Results from large clinical studies have demonstrated an association between high densities of cytotoxic and memory TILs in the tumor compartments with improved prognosis. Importantly, we have demonstrated that differential combined densities of immune infiltrates jointly analyzed in the tumor center (TC) and the invasive margin (IM) have a significant prognostic value in breast cancer patients with poor clinicopathological parameters.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–723. https://doi.org/10.1016/j.cell.2017.01.017 CrossRefPubMedPubMedCentral

Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148. https://doi.org/10.1016/j.immuni.2004.07.017 CrossRefPubMed

Zhu J, Petit PF, Van den Eynde BJ (2018) Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-018-2269-y CrossRefPubMedPubMedCentral

Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22(2):215–222. https://doi.org/10.1016/j.coi.2010.02.006 CrossRefPubMed

Spranger S (2016) Tumor heterogeneity and tumor immunity: a chicken-and-egg problem. Trends Immunol 37(6):349–351. https://doi.org/10.1016/j.it.2016.04.008 CrossRefPubMed

Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734. https://doi.org/10.1038/nrclinonc.2017.101 CrossRefPubMed

Baxevanis CN, Perez SA (2015) Cancer dormancy: a regulatory role for endogenous immunity in establishing and maintaining the tumor Dormant state. Vaccines (Basel) 3(3):597–619. https://doi.org/10.3390/vaccines3030597 CrossRef

Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautes-Fridman C (2018) Immune-based identification of cancer patients at high risk of progression. Curr Opin Immunol 51:97–102. https://doi.org/10.1016/j.coi.2018.03.005 CrossRefPubMed

Church SE, Galon J (2017) Regulation of CTL infiltration within the tumor microenvironment. Adv Exp Med Biol 1036:33–49. https://doi.org/10.1007/978-3-319-67577-0_3 CrossRefPubMed

10.

Fang D, Zhu J (2017) Dynamic balance between master transcription factors determines the fates and functions of CD4 T cell and innate lymphoid cell subsets. J Exp Med 214(7):1861–1876. https://doi.org/10.1084/jem.20170494 CrossRefPubMedPubMedCentral

11.

Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179. https://doi.org/10.1038/srep15179 CrossRefPubMedPubMedCentral

12.

Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63(1):67–72. https://doi.org/10.1007/s00262-013-1490-y CrossRefPubMed

13.

Whiteside TL (2015) The role of regulatory T cells in cancer immunology. Immunotargets Ther 4:159–171. https://doi.org/10.2147/ITT.S55415 CrossRefPubMedPubMedCentral

14.

Shou J, Zhang Z, Lai Y, Chen Z, Huang J (2016) Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. BMC Cancer 16:687. https://doi.org/10.1186/s12885-016-2732-0 CrossRefPubMedPubMedCentral

15.

Whiteside TL (2012) Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 61(2):283–288. https://doi.org/10.1007/s00262-011-1171-7 CrossRefPubMed

16.

Asano Y, Kashiwagi S, Goto W, Kurata K, Noda S, Takashima T, Onoda N, Tanaka S, Ohsawa M, Hirakawa K (2016) Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg 103(7):845–854. https://doi.org/10.1002/bjs.10127 CrossRefPubMed

17.

Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A, Tada H, Watanabe G, Nemoto N, Nakagawa S, Ishida T, Ohuchi N (2014) Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 148(3):525–534. https://doi.org/10.1007/s10549-014-3197-y CrossRefPubMed

18.

Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F (2014) Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol 25(8):1570–1577. https://doi.org/10.1093/annonc/mdu183 CrossRefPubMed

19.

Chan MS, Wang L, Felizola SJ, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H (2012) Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients—an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers 27(4):e295–e304. https://doi.org/10.5301/JBM.2012.10439 CrossRefPubMed

20.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463–1469. https://doi.org/10.1126/science.aaf1490 CrossRefPubMedPubMedCentral

21.

Creighton CJ (2012) The molecular profile of luminal B breast cancer. Biologics 6:289–297. https://doi.org/10.2147/BTT.S29923 CrossRefPubMedPubMedCentral

22.

Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Gyorffy B, Dietel M, Loibl S, Weichert W, Stenzinger A (2015) Classical pathology and mutational load of breast cancer—integration of two worlds. J Pathol Clin Res 1(4):225–238. https://doi.org/10.1002/cjp2.25 CrossRefPubMedPubMedCentral

23.

Munn DH, Bronte V (2016) Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 39:1–6. https://doi.org/10.1016/j.coi.2015.10.009 CrossRefPubMed

24.

Rothenberger NJ, Somasundaram A, Stabile LP (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19 (2). https://doi.org/10.3390/ijms19020611 CrossRefPubMedCentral

25.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899–905. https://doi.org/10.1038/nature08822 CrossRefPubMedPubMedCentral

26.

Teh JLF, Aplin AE (2018) Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-1967 CrossRefPubMedPubMedCentral

27.

Whiteside TL (2014) Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther 14(10):1411–1425. https://doi.org/10.1517/14712598.2014.927432 CrossRefPubMedPubMedCentral

28.

deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18(11):3022–3029. https://doi.org/10.1158/1078-0432.CCR-11-3216 CrossRefPubMed

29.

Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27(4):462–472. https://doi.org/10.1016/j.ccell.2015.02.015 CrossRefPubMedPubMedCentral

30.

Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S (2013) Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 62(12):1757–1768. https://doi.org/10.1007/s00262-013-1487-6 CrossRefPubMed

31.

Hoskoppal D, Reisenbichler ES (2018) Can tumor-associated macrophages in ductal carcinoma in situ (DCIS) on biopsy predict invasive carcinoma on excision? Hum Pathol. https://doi.org/10.1016/j.humpath.2018.07.023 CrossRefPubMed

32.

Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN (2017) Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. J Immunother Cancer 5:39. https://doi.org/10.1186/s40425-017-0240-7 CrossRefPubMedPubMedCentral

33.

Wu SQ, Xu R, Li XF, Zhao XK, Qian BZ (2018) Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis. Oncotarget 9(38):25294–25303. https://doi.org/10.18632/oncotarget.25334 CrossRefPubMedPubMedCentral

34.

Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, Rezai M, Dohnal K, Tesch H, Hansmann ML, Salat C, Beer M, Schneeweiss A, Sinn P, Bankfalvi A, Darb-Esfahani S, von Minckwitz G, Sinn BV, Kronenwett R, Weber K, Denkert C, Loibl S (2018) Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol 31(4):607–615. https://doi.org/10.1038/modpathol.2017.171 CrossRefPubMed

35.

Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O’Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R (2016) Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29(10):1155–1164. https://doi.org/10.1038/modpathol.2016.109 CrossRefPubMed

36.

Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS (2017) Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy 9(11):913–927. https://doi.org/10.2217/imt-2017-0052 CrossRefPubMedPubMedCentral

37.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59–73. https://doi.org/10.1038/nri2216 CrossRefPubMed

38.

Liljenfeldt L, Gkirtzimanaki K, Vyrla D, Svensson E, Loskog AS, Eliopoulos AG (2014) Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol Immunother 63(3):273–282. https://doi.org/10.1007/s00262-013-1507-6 CrossRefPubMed

39.

Fritzell S, Sanden E, Eberstal S, Visse E, Darabi A, Siesjo P (2013) Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunol Immunother 62(9):1463–1474. https://doi.org/10.1007/s00262-013-1449-z CrossRefPubMed

40.

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113. https://doi.org/10.1200/JCO.2009.23.7370 CrossRefPubMed

41.

Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G (2016) Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy. Cancer Res 76(11):3122–3126. https://doi.org/10.1158/0008-5472.CAN-16-0294 CrossRefPubMed

42.

Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57(11):1579–1587. https://doi.org/10.1007/s00262-008-0505-6 CrossRefPubMed

43.

Nawaz S, Heindl A, Koelble K, Yuan Y (2015) Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod Pathol 28(12):1621. https://doi.org/10.1038/modpathol.2015.133 CrossRefPubMed

44.

Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, Darcy PK, Loi S (2015) Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med 13:202. https://doi.org/10.1186/s12916-015-0431-3 CrossRefPubMedPubMedCentral

45.

Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S (2017) Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol 7:156. https://doi.org/10.3389/fonc.2017.00156 CrossRefPubMedPubMedCentral

46.

McIntire PJ, Irshaid L, Liu Y, Chen Z, Menken F, Nowak E, Shin SJ, Ginter PS (2018) Hot spot and whole-tumor enumeration of CD8(+) tumor-infiltrating lymphocytes utilizing digital image analysis is prognostic in triple-negative breast cancer. Clin Breast Cancer. https://doi.org/10.1016/j.clbc.2018.04.019 CrossRefPubMed

47.

Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J (2016) Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med 14(1):227. https://doi.org/10.1186/s12967-016-0983-9 CrossRefPubMedPubMedCentral

48.

Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39(1):11–26. https://doi.org/10.1016/j.immuni.2013.07.008 CrossRefPubMed

49.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257):207–211. https://doi.org/10.1126/science.aad0095 CrossRefPubMedPubMedCentral

50.

Popovic A, Jaffee EM, Zaidi N (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128(8):3209–3218. https://doi.org/10.1172/JCI120775 CrossRefPubMedPubMedCentral

51.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S (2017) Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol 1036:19–31. https://doi.org/10.1007/978-3-319-67577-0_2 CrossRefPubMedPubMedCentral

52.

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboue R, Frebourg T, Pages F, Valge-Archer V, Latouche JB, Galon J (2016) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3):698–711. https://doi.org/10.1016/j.immuni.2016.02.025 CrossRefPubMed

53.

Tokalov SV, Abolmaali ND (2010) Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer 10:57. https://doi.org/10.1186/1471-2407-10-57 CrossRefPubMedPubMedCentral

54.

Middel P, Brauneck S, Meyer W, Radzun HJ (2010) Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 10:578. https://doi.org/10.1186/1471-2407-10-578 CrossRefPubMedPubMedCentral

55.

Moussion C, Girard JP (2011) Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479(7374):542–546. https://doi.org/10.1038/nature10540 CrossRefPubMed

56.

Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP (2011) Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 71(17):5678–5687. https://doi.org/10.1158/0008-5472.CAN-11-0431 CrossRefPubMed

57.

Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pages F, Valge-Archer V, Galon J (2016) The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 8(327):327ra326. https://doi.org/10.1126/scitranslmed.aad6352 CrossRef

58.

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35):5944–5951. https://doi.org/10.1200/JCO.2008.19.6147 CrossRefPubMed

59.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. https://doi.org/10.1200/JCO.2010.30.5425 CrossRefPubMed

60.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, Andre F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kummel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33(9):983–991. https://doi.org/10.1200/JCO.2014.58.1967 CrossRefPubMed

61.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Janne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM (2018) Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 50(9):1271–1281. https://doi.org/10.1038/s41588-018-0200-2 CrossRefPubMedPubMedCentral

62.

Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R (2017) Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 23(15):4242–4250. https://doi.org/10.1158/1078-0432.CCR-16-3133 CrossRefPubMedPubMedCentral

63.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bosse D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359(6377):801–806. https://doi.org/10.1126/science.aan5951 CrossRefPubMedPubMedCentral

64.

Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18(3):197–218. https://doi.org/10.1038/s41573-018-0007-y CrossRefPubMed

Titel: The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
verfasst von: Constantin N. Baxevanis
Michael Sofopoulos
Sotirios P. Fortis
Sonia A. Perez
Publikationsdatum: 23.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 10/2019
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02327-7

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The role of immune infiltrates as prognostic biomarkers in patients with breast cancer

Abstract

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients

Unlocking the therapeutic potential of primary tumor-draining lymph nodes

“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany

ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie